[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bone-fracture\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bone-fracture":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,46,77,106,133,159,183,210],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100287618","phase-1-enhancement-of-bone-regeneration-and-healing-in-the-extremities-by-the-use-of-autologous-bonofill-ii-100287618",false,"NCT03024008","Enhancement of Bone Regeneration and Healing in the Extremities by the Use of Autologous BonoFill-II","A Multicenter Study to Evaluate the Enhancement of Bone Regeneration and Healing in the Extremities by the Use of Autologous BonoFill-II","Inclusion Criteria:\n\n* Long and short bones extra articular comminuted fracture or\n* Long and short bones extra and intra articular defect\u002Fgap or non union, incapable of self-regeneration\n\nExclusion Criteria:\n\n* Age is under 18 or above 80\n* A simple fracture manageable by one definitive treatment\n* Pregnant or lactating women\n* Patients with active infection that is in question and needs osteogenic treatment.\n* More than 3 previous failed interventions at the surgical site\n* History of advanced congestive heart failure or active acute myocardial infarction (AMI), renal failure (estimated GFR of \\\u003C30 ml\u002Fmin\u002F1.73 m2 at screening), or hepatic disease (hepatic insufficiency classified as Child-Pugh B or C)\n* Diabetic subjects (HbA1c \\> 8)\n* Subject treated currently with systemic steroids.\n* Subjects with known autoimmune diseases, such as Addison's disease, Celiac disease - sprue (gluten-sensitive enteropathy), Dermatomyositis, Graves disease, Hashimoto's thyroiditis, Multiple sclerosis, Myasthenia gravis, Pernicious anemia, Reactive arthritis, Rheumatoid arthritis, Sjogren syndrome, Systemic lupus erythematosus.\n* Subjects diagnosed with osteoporosis\n* Chronic severe PVD (Peripheral Vascular Disease) subjects\n* Post major vascular operation in the treated limb\u002Fs and above the surgical site (with or without Gore-Tex grafting)\n* Subjects that have a known scar healing problem (keloid formation).\n* Subjects treated with Bisphosphonate drugs\n* Oncology patient or subjects who received chemotherapy or radiotherapy treatment in the past 12 months\n* Immunocompromised condition from any reason, at screening\n* Subjects participating in another clinical trial 30 days prior to and during the study period.\n* Drug addicts and psychiatric patients patients incapable of giving consent.\n* Subjects with a known history of any significant medical disorder, which in the investigator's judgment contraindicates the subject's participation\n* Subjects with any known allergy for local\u002Fgeneral anesthesia\n* Positive serology for either HIV, hepatitis B or hepatitis C\n* Abnormal clinically significant laboratory test and findings, as per the investigator's judgment","ALL","18 Years","80 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","The purpose of this clinical study is to evaluate the safety and the efficacy of BonoFill-II as an autologous bone-regenerating graft in the reconstruction of deficient bone in two clinical indications:\n\n1. Long and short bone extra-articular comminuted fracture\n2. Long and short bones extra and intra articular defect \u002FGap or non-union, incapable of self-regeneration",[28],"Bone Fracture",[30,31,32],"Critical Gap","Comminuted Fracture","Extra-Articular","RECRUITING","2025-12-03",{"date":36,"type":37},"2025-12-10","ACTUAL",{"date":39,"type":37},"2017-07-27",{"date":41,"type":21},"2027-06",{"name":43,"class":44},"BonusBio Group Ltd","INDUSTRY",6,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100507119","phase-1-sustained-acoustic-medicine-sam-for-symptomatic-treatment-of-pain-related-to-bone-fracture-100507119","NCT05883241","Sustained Acoustic Medicine (SAM) for Symptomatic Treatment of Pain Related to Bone Fracture","Inclusion Criteria:\n\n* Have physician-diagnosed bone fracture\n* Are between 18-80 years of age\n* Report a pain score between 3-7 (range: 0-10) prior to enrolment\n* Report that pain from fracture negatively affects quality of life\n* Are willing not to use any cream, gel, or topical solution during the administration of treatment other than the approved treatment provided to the subject at the initiation of the study\n* Are deemed appropriate by their physician or by the study site physician to participate.\n* Be willing and able to self-administer treatment daily within their place of residence or during normal daily activity, excluding bathing, showering, or other water activities which may result in submersion of the study device.\n* Not use or initiate opioid and\u002For non-opioid analgesic medications.\n* Be willing to discontinue any other interventional treatment modalities on the affected area during the study period (e.g., transcutaneous electrical nerve stimulation, electronic muscle stimulation, traditional ultrasound).\n\nExclusion Criteria:\n\n* Cannot successfully demonstrate the ability to put on and take off the device.\n* Displays any condition which, in the judgment of the investigator, would make participation in the study unacceptable including, but not limited to, the subject's ability to understand and follow instructions.\n* Participated in a clinical trial for an investigational drug and\u002For agent within 30 days prior to screening.\n* Is pregnant.\n* Is a prisoner.\n* Is non-ambulatory (unable to walk).\n* Has a pacemaker.\n* Has a malignancy in the treatment area.\n* Has an active infection, open sores, or wounds in the treatment area.\n* Has impaired sensation in the treatment area, such as caused by chemotherapy or anesthesia.\n* Has a known neuropathy (disease of the brain or spinal nerves).\n* Has a hereditary disposition (tendency) for excessive bleeding (hemorrhage).\n* Are currently taking steroids.",true,{"count":54,"type":21},90,[24],"The purpose of this study is to assess the ability of long-duration low-intensity therapeutic ultrasound (LITUS) to alleviate bone-fracture related pain over a 12-week period.\n\nThe primary objective of this study is to evaluate the analgesic effect of LITUS in subjects suffering from bone-fracture pain.\n\nSecondary objectives are to assess the ability of LITUS to improve patients return to work time.",[28,58],"Fresh Fracture",[60,61,62,63,64,65,66],"Low-Intensity Ultrasound","Drug Delivery","Sonophoresis","Transdermal Drug Delivery","Non-Steroidal Anti-Inflammatory Drugs","Sustained Acoustic Medication","Low-Intensity Continuous Ultrasound","2025-02-25",{"date":69,"type":37},"2025-02-28",{"date":71,"type":37},"2023-06-01",{"date":73,"type":21},"2026-02-28",{"name":75,"class":44},"ZetrOZ, Inc.",2,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":105},"100524813","effects-of-photobiomodulation-on-functional-recovery-of-proximal-humerus-fractures-100524813","NCT06113614","Effects of Photobiomodulation on Functional Recovery of Proximal Humerus Fractures","Effects of Photobiomodulation on Functional Recovery of Proximal Humerus Fractures: a Double-blind Randomized Controlled Clinical Study","The subjects selected for inclusion will be individuals of both genders treated at HMACN hospital, with isolated and closed proximal humerus fractures with displacement and surgical indication, undergoing open reduction and internal fixation (ORIF) with a locking angular stability plate for the proximal humerus (Neer 1070, Carrera et al., 2012; Petros, 2019), and meeting the following eligibility criteria.\n\nIndividuals aged between 18 and 65 years, of both genders, with proximal humerus fractures classified as:\n\nNeer group III Neer group IV Neer group V AO\u002FOTA subgroups A2 and A3 AO\u002FOTA group B AO\u002FOTA group C (only for patients under 55 years of age)\n\nExclusion criteria:\n\nIndividuals with pre-existing injuries or sequelae in the shoulder and shoulder girdle or motor deficits due to central or peripheral neurological injuries; Individuals with pathological fractures; Individuals who develop postoperative infection or implant loosening; Individuals with ipsilateral fractures in other regions of the limb; Individuals with neurovascular injuries causing sensory deficits at the injury site; Individuals with local or systemic conditions contraindicating surgical intervention or complicating postoperative recovery; Individuals with a history of photosensitivity; Individuals with neurological or psychiatric disorders; Individuals with proliferative or infectious skin lesions in the shoulder region receive LED light; Individuals who used anti-inflammatory drugs within five days before the trauma; Pregnant women; Individuals with surgical complications such as neurological or vascular injuries or fracture line extension during surgery will not meet the desired evolution pattern.","65 Years",{"count":86,"type":21},42,[88],"NA","Among the various complications of the postoperative evolution of proximal humerus fractures (PHF) are pain and joint stiffness, generating significant functional limitation in the affected limb. This randomized controlled double-blind clinical study aims to evaluate the effects of photobiomodulation (PBM) on the functional recovery of participants with PHF surgically treated with special locking plates. The primary outcome, to be assessed at 1, 2, 4, 8, and 12 weeks, will be shoulder function recovery using the Quick-DASH functional scale. Secondary outcomes will include shoulder range of motion assessments with a digital goniometer, quality of life measured using the SF-6 questionnaire, and the occurrence of adverse effects during all experimental periods. Pain will be evaluated at 1, 2, 4, 8, and 12 weeks; fracture consolidation will be assessed through radiographic examinations at 4, 8, and 12 weeks; and muscular strength will be evaluated through progressive weight-bearing exercises at 8 and 12 weeks. Data will be presented as means ± SD, with significance set at a p-value of 0.05.",[28,91,92],"Humerus Fracture","Surgery",[94],"photobiomodulation","2024-11-16",{"date":97,"type":37},"2024-11-19",{"date":99,"type":37},"2024-04-30",{"date":101,"type":21},"2026-04-30",{"name":103,"class":104},"University of Nove de Julho","OTHER",1,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":52,"sex":16,"minAge":113,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":117,"phases":4,"briefSummary":118,"conditions":119,"keywords":122,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":76},"100403065","the-impact-of-glomerular-disorders-on-bone-quality-and-strength-100403065","NCT04528446","The Impact of Glomerular Disorders on Bone Quality and Strength","BoneGN","Inclusion Criteria for participants with glomerular disease:\n\n1. CureGN participant or CureGN Eligible\n\n   CureGN eligible is defined as having a diagnosis of Glomerulonephropathy (GN). Patients would otherwise be enrolled in be in CureGN study, except for lacking a minor entry criteria, such as:\n   1. First diagnostic kidney biopsy within 5 years of CureGN study enrollment\n   2. Access to first kidney biopsy report and\u002For slides or not being interested in study participation.\n2. Males or females 5 to 55 years (premenopausal for women)\n3. Females must have a negative urine\u002Fserum pregnancy test\n4. Stable doses of nutritional vitamin D or active vitamin D therapy for at least 3 months before enrollment ((if on either form of Vitamin D)\n5. Consent\u002FParental\u002Fguardian permission (informed consent) and if appropriate, child assent\n\nExclusion Criteria for all participants\n\n1. Chronic Dialysis\n2. Solid organ transplantation\n3. Lower extremity amputations or non-ambulatory\n4. Malignancy requiring chemotherapy or metastatic to bone\n5. Metabolic bone disease (e.g., Paget's disease, primary hyperparathyroidism)\n6. Endocrinopathy (current hyperthyroidism or untreated hypothyroidism, Cushing's syndrome)\n7. Medical diseases (end stage liver disease, heart or lung disease, intestinal malabsorption)\n8. Those treated with bisphosphonates, teriparatide, calcitonin, selective estrogen receptor modulators, estrogen, or phenytoin in the past 12 months\n9. Previous bilateral wrist and tibia fractures\n10. Pregnant or lactating females\n11. Parents\u002Fguardians or participants who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.","5 Years","55 Years",{"count":116,"type":21},270,"OBSERVATIONAL","The primary objectives of this study are to: (1) determine the impact of glomerular disease on bone strength and (2) investigate the pathophysiologic underpinnings of impaired bone strength in glomerular disease.",[120,121,28],"Glomerular Disease","Bone Diseases, Metabolic",[123,28],"Kidney Disease","2024-06-28",{"date":126,"type":37},"2024-07-01",{"date":128,"type":37},"2019-06-14",{"date":130,"type":21},"2024-12",{"name":132,"class":104},"Columbia University",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":84,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":142,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":105},"100535290","efficacy-of-bioceramic-materials-for-bone-defects-repair-100535290","NCT06249906","Efficacy of Bioceramic Materials for Bone Defects Repair","Clinical Study of Bioceramic Materials in Bone Defect Repair","Inclusion Criteria:\n\n1. Patients who voluntarily take the test and sign the informed consent form;\n2. Patients aged 18-65 years old with no history of allergies;\n3. Patients able to communicate well with the investigator and follow the requirements of the entire trial.\n\nExclusion Criteria:\n\n1. Patients who refuse to sign the informed consent form to participate in the trial;\n2. Patients who are not in the age range of 18 to 65 years;\n3. Patients with diseases unsuitbale for the trial: history of allergies, severe cardiopulmonary disease, coagulation dysfunction, Alzheimer's disease, cerebral atrophy, acute phase or sequelae of cerebrovascular disease, cognitive impairment;\n4. Patients in the acute phase of local or systemic bacterial infections;\n5. Patients who cannot cooperate with the operation and evaluate the effect;\n6. Other conditions that are considered inappropriate by the investigator to participate in the study.",{"count":141,"type":21},10,[88],"The purpose of this study is to demonstrate the effect of bioceramic implants on the repair of human bone defects, and to explore the application of bioceramic materials in bone defects, bone implantation, and bone fusion. The surface microstructure of β-tricalcium phosphate bioceramic implants can be effectively controlled to guide the regeneration of bones, promote the restoration of bones, accelerate the speed of recovery, and improve bone quality, which is of great clinical and social significance.",[145,146,147,28,148,149],"Bone Lesion","Cartilage Degeneration","Osteo Arthritis Knee","Bone Injury","Bone Loss","2024-03-08",{"date":152,"type":37},"2024-03-12",{"date":154,"type":37},"2024-02-20",{"date":156,"type":21},"2026-12-30",{"name":158,"class":104},"Nanjing First Hospital, Nanjing Medical University",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":166,"enrollmentInfo":167,"targetDuration":4,"studyType":117,"phases":4,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":5},"100495566","osteomics-identifying-regulators-of-bone-homeostasis-100495566","NCT05732870","OSTEOMICS: Identifying Regulators of Bone Homeostasis","OSTEOMICS","Inclusion Criteria:\n\n1. Patients with osteoarthritis undergoing total joint arthroplasty, osteotomy or arthrodesis of any joint (including hip, knee, shoulder, wrist, elbow, ankle).\n2. Patient with fractured neck of femurs undergoing hemiarthroplasty or total hip arthroplasty, or other internal fixation procedure.\n3. Patients undergoing acute low-velocity or fragility fracture fixation surgery.\n4. Patients aged between 18-110 years old with capacity to consent.\n\nSince deteriorating bone health including diseases like osteoporosis are primarily conditions of older age there is no practical upper age-limit. However, study involvement is limited by suitability for surgery which encompasses multiple factors considered on an individual case basis including age, frailty, comorbidities, baseline mobility, renal function and ability to consent (for instance due to dementia or delirium).\n\nWe note that our inclusion criteria is purposefully broad as we aim to deduce trends across a wide range of conditions and backgrounds.\n\nExclusion Criteria:\n\n1. Patients unable to provide informed consent.\n2. Patients with suspected\u002Festablished underlying malignancy.\n3. Patients with suspected\u002Festablished osteomyelitis.\n4. Patients with suspected\u002Festablished bloodborne disease\n5. Patients who are currently a subject of a clinical trial involving an investigational medicinal product.","110 Years",{"count":168,"type":21},2000,"Diseases of bone associated with ageing, including osteoporosis (OP) and osteoarthritis (OA), reduce bone mass, bone strength and joint integrity. Current non-surgical approaches are limited to pharmaceutical agents that are not disease modifying and have poor patient tolerability due to side effect profiles. Developing a fundamental understanding of cellular bone homeostasis, including how key cell types affect tissue health, and offering novel therapeutic targets for prevention of bone disease is therefore essential. This is the focus of OSTEOMICS.\n\nA number of factors have been linked to increased risk of bone disease, including genetic predisposition, diet, smoking, ageing, autoimmune disorders and endocrine disorders. In our study, we will recruit patients undergoing elective and non-elective orthopaedic surgery and obtain surgical bone waste for analysis. This will capture a cohort of patients with bone disorders like OP and OA, in addition to patients without overt clinical bone disease. We will study the relationship between the molecular biology of bone cells, bone structure, genetics (DNA) and environmental factors with the aim of identifying and validating novel therapeutic targets.\n\nWe will leverage modern single cell technologies to understand the diversity of cell types found in bone. These technologies have now led to the characterisation of virtually every tissue in the body, however bone and bone-adjacent tissues are massively underrepresented due to the anatomical location and underlying technical challenges. Early protocols to demineralise bone and perform single cell profiling have now been developed. We will systematically scale up these efforts to observe how genetic variation at the population level leads to alterations in bone structure and quality.\n\nOver the next 10 years, we will generate data to comprehensively characterise bone across health and disease, use machine learning to drive analysis, and experimentally validate hypotheses - which will ultimately contribute to developing the next generation of therapeutic agents.",[171,172,173,28,174],"Osteoporosis","Osteoarthritis","Bone Diseases","Bone Marrow Disease",{"date":176,"type":37},"2024-02-23",{"date":178,"type":37},"2023-01-12",{"date":180,"type":21},"2032-12",{"name":182,"class":44},"Relation Therapeutics",{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":190,"minAge":191,"maxAge":192,"enrollmentInfo":193,"targetDuration":4,"studyType":117,"phases":4,"briefSummary":195,"conditions":196,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":105},"100345971","metabolic-and-bone-changes-after-adjuvant-cancer-treatments-in-early-non-metastatic-breast-cancer-100345971","NCT03784651","Metabolic and Bone Changes After Adjuvant Cancer Treatments in Early Non-metastatic Breast Cancer","Metabolic and Bone Changes After Adjuvant Cancer Treatments in Early Non-metastatic Breast Cancer - a 5-year Follow-up Study.","Inclusion Criteria:\n\n* Postmenopausal\n* Breast cancer stage I-III\n* Eligible to receive (neo-)adjuvant chemotherapy\u002Fother antineoplastic treatment\n\nExclusion Criteria:\n\n* Prior malignancy\n* Metabolic disease (diabetes mellitus etc)","FEMALE","50 Years","70 Years",{"count":194,"type":21},120,"Breast cancer is the most common cancer type in European women. Patients treated for early non-metastatic breast cancer comprise a growing group of survivors due to early diagnosis and improved treatment. Many of these survivors experience adverse effects such as decreased bone mineral density, derangement of metabolic markers (fat, glucose, insulin) and increased blood pressure. Increasing risk of bone fracture and cardiometabolic disease (eg. diabetes mellitus type 2).\n\nThe purpose of this study is to identify mechanisms behind cardiometabolic changes that may be connected to the (neo-)adjuvant treatment. On top of this we hope to indentify potential biological markers that can help prevent development of metabolic disease.\n\nWe will be recruiting 120 post-menopausal women age 50-70 with early breast cancer and 1-2 times a year for 5 years examine bone mineral density, body composition, glucose and fat metabolism and nerve damage. A questionnaire will be used to collect information on diet, physical activity and quality of life. Derudover anvendes spørgeskemaer til at indsamle information vedrørende. This new knowledge will help clinicians start adequate preventive measures to help patients avoid cardiometabolic disease secondary to cancer treatment.",[28,197,198,199,200],"Glucose, High Blood","Insulin Resistance","Blood Pressure, High","Cholesterolemia","2021-09-14",{"date":203,"type":37},"2021-09-16",{"date":205,"type":37},"2018-12-17",{"date":207,"type":21},"2026-11",{"name":209,"class":104},"Rigshospitalet, Denmark",{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":214,"acronym":215,"eligibilityCriteria":216,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":217,"targetDuration":219,"studyType":117,"phases":4,"briefSummary":220,"conditions":221,"keywords":222,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":105},"100262167","healtheast-community-hip-and-knee-replacement-registry-100262167","NCT02692092","HealthEast Community Hip and Knee Replacement Registry","HEJR","Inclusion Criteria:\n\n* Total Hip or Total Knee Arthroplasty\n* HealthEast acute care hospital\n\nExclusion Criteria:\n\n* Age\\\u003C18\n* Primary procedure not performed at a HealthEast hospital",{"count":218,"type":21},200000,"40 Years","HealthEast Care System began the first community-based joint replacement registry (HJRR) in the U.S. in 1991, and now has more than 30,000 total joints registered. The purpose of the HJRR is to maintain and improve the care of individuals undergoing joint replacement surgery by providing timely information to their surgeons and the broader orthopaedic community.\n\nAs it moves into the third decade, the HJRR is proud of its role in the development of the national American Joint Replacement Registry (AJRR) and will remain an important contributor to the larger national effort in the advancement of orthopaedic science.",[28],[223,224,225],"Complications","Arthroplasty, Hip Replacement","Arthroplasty, Knee Replacement","2018-02-23",{"date":228,"type":37},"2018-02-26",{"date":230,"type":4},"1991-09",{"date":232,"type":21},"2091-08",{"name":234,"class":104},"HealthEast Care System"]